Capricor Therapeutics (CAPR) Misses Q2 EPS by 9c

Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.57), $0.09 worse than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Kaos Capital pushes for board changes at Capricor Therapeutics
• Boeing names Ryan Shedd as new SVP and controller
• Nuvectis Pharma (NVCT) files $200M mixed shelf